Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-29
2008-07-29
Shiao, Rei-tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S302700
Reexamination Certificate
active
07405234
ABSTRACT:
The invention provides compounds according to formula Iwherein the substitutents are as described herein.Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia. Also provided are pharmaceutical compositions containing such compounds and processes for preparing some of the compounds of the invention.
REFERENCES:
patent: 3239345 (1966-03-01), Hodge et al.
patent: 3948933 (1976-04-01), Fontanella
patent: 4036979 (1977-07-01), Asato
patent: 4411890 (1983-10-01), Momany
patent: 4859684 (1989-08-01), Raeymaekers et al.
patent: 4959361 (1990-09-01), Walser
patent: 5179080 (1993-01-01), Rothkopf
patent: 5403817 (1995-04-01), Seckinger et al.
patent: 5482921 (1996-01-01), Seckinger et al.
patent: 5488064 (1996-01-01), Sher
patent: 5491134 (1996-02-01), Sher et al.
patent: 5541204 (1996-07-01), Sher et al.
patent: 5556909 (1996-09-01), Desai et al.
patent: 5605877 (1997-02-01), Schafer et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5688808 (1997-11-01), Jones et al.
patent: 5688810 (1997-11-01), Jones et al.
patent: 5693646 (1997-12-01), Jones et al.
patent: 5693647 (1997-12-01), Jones et al.
patent: 5696127 (1997-12-01), Jones et al.
patent: 5696130 (1997-12-01), Jones et al.
patent: 5696133 (1997-12-01), Jones et al.
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5811374 (1998-09-01), Bertram et al.
patent: 6011029 (2000-01-01), Ding et al.
patent: 6040321 (2000-03-01), Kim et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6184231 (2001-02-01), Hewawasam et al.
patent: 6310095 (2001-10-01), Sebti et al.
patent: 6365615 (2002-04-01), Kelly et al.
patent: 6531612 (2003-03-01), Gabriel et al.
patent: 6566387 (2003-05-01), Palovich et al.
patent: 6670386 (2003-12-01), Sun et al.
patent: 6710064 (2004-03-01), Launay et al.
patent: 6897225 (2005-05-01), Sircar et al.
patent: 6992102 (2006-01-01), Hamann et al.
patent: 7256208 (2007-08-01), Yingzhi et al.
patent: 2002/0133004 (2002-09-01), Takaai
patent: 2005/0059652 (2005-03-01), Hamann et al.
patent: 2005/0182105 (2005-08-01), Nirschl et al.
patent: 2005/0187267 (2005-08-01), Hamann et al.
patent: 2005/0197359 (2005-09-01), Nirdchl et al.
patent: 2005/0197367 (2005-09-01), Li et al.
patent: 2007/0004717 (2007-01-01), Li et al.
patent: A-82875/87 (1988-06-01), None
patent: 2126187 (1971-05-01), None
patent: 38 09 390 (1989-09-01), None
patent: 0 272 594 (1987-12-01), None
patent: 0 493323 (1992-01-01), None
patent: 1 004 583 (2000-05-01), None
patent: 1125925 (2001-08-01), None
patent: 1 503 244 (1978-03-01), None
patent: 52 083686 (1977-07-01), None
patent: WO89/07110 (1989-08-01), None
patent: WO89/07111 (1989-08-01), None
patent: WO93/04081 (1993-03-01), None
patent: WO94/05668 (1994-03-01), None
patent: WO94/14817 (1994-07-01), None
patent: WO96/19458 (1996-06-01), None
patent: WO97/19086 (1997-05-01), None
patent: WO97/21993 (1997-06-01), None
patent: WO97/30992 (1997-08-01), None
patent: WO97/49709 (1997-12-01), None
patent: WO98/22461 (1998-05-01), None
patent: WO98/25929 (1998-06-01), None
patent: WO98/38192 (1998-09-01), None
patent: WO98/54966 (1998-12-01), None
patent: WO99/00353 (1999-01-01), None
patent: WO99/01124 (1999-01-01), None
patent: WO99/02224 (1999-01-01), None
patent: WO99/02514 (1999-01-01), None
patent: WO99/03848 (1999-01-01), None
patent: WO99/07692 (1999-02-01), None
patent: WO99/24416 (1999-05-01), None
patent: WO99/27890 (1999-06-01), None
patent: WO99/28324 (1999-06-01), None
patent: WO99/43653 (1999-09-01), None
patent: WO99/54318 (1999-10-01), None
patent: WO99/54319 (1999-10-01), None
patent: WO99/54330 (1999-10-01), None
patent: WO99/65913 (1999-12-01), None
patent: WO99/67252 (1999-12-01), None
patent: WO99/67253 (1999-12-01), None
patent: WO 00/00485 (2000-01-01), None
patent: WO 00/01389 (2000-01-01), None
patent: WO 00/13508 (2000-03-01), None
patent: WO0059874 (2000-10-01), None
patent: WO00/72845 (2000-12-01), None
patent: WO 01/07052 (2001-02-01), None
patent: WO 01/16108 (2001-03-01), None
patent: WO 01/16133 (2001-03-01), None
patent: WO 01/16139 (2001-03-01), None
patent: WO 01/30781 (2001-05-01), None
patent: WO 01/46195 (2001-06-01), None
patent: WO0154498 (2001-08-01), None
patent: WO0170684 (2001-09-01), None
patent: WO0172705 (2001-10-01), None
patent: WO 02/00653 (2002-01-01), None
patent: WO0218335 (2002-07-01), None
patent: WO 03/011824 (2003-02-01), None
patent: WO 03/066636 (2003-08-01), None
Issartel et al.,1996, CAS: 125:316198.
Palovich et al., 2000, CAS: 134:25357.
Panouse, J. et al., “Relations structures-Activities des immunomodulateurs apport de la modelisation moleculaire. Immunimodulator structure-Activity Relationships: Contribution of Molecular Modeling”, Annales Pharmaceutiques Francaises, Masson. Paris, FR, pp. 291-302 (2000).
Talon, S. et al., “Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na+channels enhancing the antimyotonic activity in vivo”, British J. of Pharmacology, vol. 134(7), pp. 1523-1531 (2001).
Uozumi, Y. et al., “Enantioselective desymmetrization ofmeso-cyclic anhydrides catalyzed by hexahydro-1H-pyrrolo [1,2-c] imidazolones”, Tetrahedron Letters, vol. 42(3), pp. 411-414 (2001).
Alexey B. Dyatkin, (1997) Tetrahedron Letters, vol. 38, No. 12, pp. 2065-2066.
Banz, W.J. et al., “Effects of Soy Protein and Soy Phytoestrogens on Symptoms Associated with Cardiovascular Disease in Rats”, Journal of Medicinal Food, vol. 2, Nos. 3-4, pp. 271-273 (1999).
Beyler, A.L. et al., “Methods for Evaluating Anabolic and Catabolic Agents in Laboratory Animals”, Journal of the American Medical Women's Association, vol. 23, No. 8, pp. 708-721 (1968).
Boris, A. et al., “Comparative Androgenic, Myotrophic and Antigonadotrophic Properties of Some Anabolic Steroids”, Steroids, vol. 15, pp. 61-71 (1970).
Bourguet, W. et al., “Crystal Structure of the ligand-binding domain of the human nuclear receptor RXR-α”, Nature, vol. 375, pp. 377-382 (1995).
Brzozowski, A.M. et al., “Molecular basis of agonism and antagonism in the oestrogen receptor”, Nature, vol. 389, pp. 753-758 (1997).
Bundgaard, H., “Design and Application of Prodrugs”, A Textbook of Drug Design and Development, Harwood Academic Publishers, publ., Krogsgaard-Larsen, P. and Bundgaard, T., eds., pp. 113-191 (1991).
Bundgaard, H., ed., Design of Prodrugs, Elsevier Science Publishers B.V., publ., (table of contents) (1985).
Chalepakis, G. et al., “Differential Gene Activation by Glucocorticoids and Progestins Through the Hormone Regulatory Element of Mouse Mammary Tumor Virus”, Cell, vol. 53, pp. 371-382 (1988).
Delaisi, C. et al., “RU54115, A Tight-Binding Aromatase Inhibitor Potentially Useful for the Treatment of Breast Cancer”, J. Steroid Biochem. Molec. Biol., vol. 41, No. 3-8, pp. 773-777 (1992).
Edwards, J.P. et al., “Nonsteroidal Androgen Receptor Agonists Based on 4-(Trifluoromethyl)-2H-Pyrano[3,2-g]Quinolin-2-One”, Bioorganic & Medicinal Chemistry Letters, vol. 9, pp. 1003-1008 (1999).
Evans, R.M., “The Steroid and Thyroid Hormone Receptor Superfamily”, Science, vol. 240, pp. 889-895 (1988).
Gori, Z. et al., “La Ipertrofia Da Testosterone Del Muscolo Elevatore Dell'ano Di Ratto Castrato.—I) Dati Quantitativi”, Boll.-Soc. Ital. Biol. Sper., vol. 42, 1596-1599 (1966).
Gori, Z. et al., “La Ipertrofia Da Testosterone Del Muscolo Elevatore Dell'ano Di Ratto Castrato.—II) Osservazioni Al Microscopio Elettronico”, Boll.-Soc. Ital. Biol. Sper., vol. 42, 1600-1601 (1966).
Grese, T.A. et al., “Molecular determinants of tissue selectivity in estrogen receptor modulators”, Proc. Natl. Acad. Sci. USA, vol. 94, pp. 14105-14110 (1997).
Hamann, L.G. et al., “Discovery of a Potent, Orally Active, Nonsteroidal Androgen Rec
Augeri David
Bi Yingzhi
Hamann Lawrence
Holubec Alexandra
Huang Yan-Ting
Bristol--Myers Squibb Company
Feigelson Daniel
Heslin Rothenberg Farley & & Mesiti P.C.
Shiao Rei-tsang
LandOfFree
Bicyclic modulators of androgen receptor function does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic modulators of androgen receptor function, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic modulators of androgen receptor function will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2781506